- Home
- ICCC vs PLUR Comparison
ICCC vs PLUR Comparison
Compare ICCC & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCC
- PLUR
- Stock Information
- Founded
- ICCC 1982
- PLUR 2001
- Country
- ICCC United States
- PLUR Israel
- Employees
- ICCC N/A
- PLUR N/A
- Industry
- ICCC Biotechnology: Pharmaceutical Preparations
- PLUR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ICCC Health Care
- PLUR Health Care
- Exchange
- ICCC Nasdaq
- PLUR Nasdaq
- Market Cap
- ICCC 57.4M
- PLUR 36.9M
- IPO Year
- ICCC 1987
- PLUR N/A
- Fundamental
- Price
- ICCC $6.06
- PLUR $4.25
- Analyst Decision
- ICCC
- PLUR Strong Buy
- Analyst Count
- ICCC 0
- PLUR 1
- Target Price
- ICCC N/A
- PLUR $12.00
- AVG Volume (30 Days)
- ICCC 22.0K
- PLUR 9.4K
- Earning Date
- ICCC 11-12-2025
- PLUR 11-11-2025
- Dividend Yield
- ICCC N/A
- PLUR N/A
- EPS Growth
- ICCC N/A
- PLUR N/A
- EPS
- ICCC 0.20
- PLUR N/A
- Revenue
- ICCC $28,274,756.00
- PLUR $1,336,000.00
- Revenue This Year
- ICCC N/A
- PLUR $97.38
- Revenue Next Year
- ICCC N/A
- PLUR $293.97
- P/E Ratio
- ICCC $31.15
- PLUR N/A
- Revenue Growth
- ICCC 21.75
- PLUR 309.82
- 52 Week Low
- ICCC $3.38
- PLUR $3.33
- 52 Week High
- ICCC $7.60
- PLUR $7.13
- Technical
- Relative Strength Index (RSI)
- ICCC 41.50
- PLUR 42.25
- Support Level
- ICCC $6.19
- PLUR $4.20
- Resistance Level
- ICCC $6.99
- PLUR $4.61
- Average True Range (ATR)
- ICCC 0.38
- PLUR 0.25
- MACD
- ICCC -0.03
- PLUR 0.00
- Stochastic Oscillator
- ICCC 6.06
- PLUR 48.88
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.